Suppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 1, 2014, Pages 53-67

  Acosta, Y Y ^a   Montes Casado, M ^b   Aragoneses Fenoll, L ^b   Dianzani, U ^c   Portoles P ^b   Rojo, Jose M ^a  

^a CSIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

EAE; ICOS; Phosphatidyl inositol 3 kinase; PI3 K DNA dependent protein kinase

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; ANTIINFLAMMATORY AGENT; CASPASE INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHENMETRAZINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE P110ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE P110BETA; PHOSPHATIDYLINOSITOL 3 KINASE P110DELTA; PHOSPHATIDYLINOSITOL 3 KINASE P110GAMMA; PIK 75; UNCLASSIFIED DRUG; CYTOKINE; HYDRAZONE DERIVATIVE; SULFONAMIDE; CD3 ANTIBODY; CONCANAVALIN A; MONOCLONAL ANTIBODY CD28;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; LYMPHOCYTE ACTIVATION; PATHOLOGY; CELL SURVIVAL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; SPLEEN; TH2 CELL;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HYDRAZONES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; SULFONAMIDES;

EID: 84900550933     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700108     Document Type: Article

References (35)

1. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. Synthesis and function of 3-phosphorylated Inositol lipids. Annu Rev Biochem 2001; 70:535-602. (Pubitemid 32662219)
2. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11:329-41.
3. Guillermet-Guibert J, Bjorklof K, Salpekar A, et al. The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc Natl Acad Sci USA 2008; 105:8292-97. (Pubitemid 351904749)
4. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008; 27:5486-96.
5. Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. Cancer-derived mutations in the regulatory subunit p85a of phosphoinositide 3-kinase function through the catalytic subunit p11α Proc Natl Acad Sci USA 2010; 107:15547-52.
6. Fruman DA, Rommel C. PI3Kδ inhibitors in cancer: Rationale and serendipity merge in the clinic. Cancer Discov 2011; 1:562-72.
7. Deane JA, Fruman DA. Phosphoinositide 3-Kinase: Diverse roles in immune cell activation. Annu Rev Immunol 2004; 22:563-98. (Pubitemid 38680434)
8. So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012; 442:465-81.
9. Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev 2009; 228:253-72.
10. Okkenhaug K, Ali K, Vanhaesebroeck B. Antigen receptor signalling: A distinctive role for the p110δ isoform of PI3K. Trends Immunol 2007; 28:80-87. (Pubitemid 46176736)
11. Acosta Y, Zafra M, Ojeda G, Bernardone I, Dianzani U, Portolés P, Rojo J. Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278). Cell Mol Life Sci 2011; 68:3065-79.
12. Martin-Orozco N, Li Y, Wang Y, Liu S, Hwu P, Liu Y-J, Dong C, Radvanyi L. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res 2010; 70:9581-90.
13. Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008; 105:7797-802. (Pubitemid 351872718)
14. Dagia NM, Agarwal G, Kamath DV, et al. A preferential p110α/γ PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NFkB-dependent manner. Am J Physiol Cell Physiol 2010; 298:C929-41.
15. Feito MJ, Vaschetto R, Criado G, et al. Mechanisms of ICOS costimulation: Effects on proximal TCR signals and MAP kinase pathways. Eur J Immunol 2003; 33:204-14. (Pubitemid 36157658)
16. Rojo JM, Pini E, Ojeda G, Bello R, Dong C, Flavell RA, Dianzani U, Portoles P. CD4T+ICOS+ T lymphocytes inhibit T cell activation "in vitro" and attenuate autoimmune encephalitis "in vivo". Int Immunol 2008; 20:577-89. (Pubitemid 351426050)
17. Hayakawa M, Kawaguchi K-I, Kaizawa H, et al. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a] pyridines as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2007; 15:5837-44. (Pubitemid 47043472)
18. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p11α in insulin signaling. Cell 2007; 125:733-47.
19. Jamieson S, Flanagan JU, Kolekar S, et al. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 2011; 438:53-62.
20. Niedermeier M, Hennessy BT, Knight ZA, et al. Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009; 113:5549-57.
21. De Frias M, Iglesias-Serret D, Cosialls AM, et al. Isoform-selective phosphoinositide 3-kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells. Br J Haematol 2010; 150:108-10.
22. Braumuller H, Wieder T, Brenner E, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-65.
23. Schürch C, Riether C, Amrein MA, Ochsenbein AF. Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ J Exp Med 2013; 210:605-21.
24. Ramadani F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, Corcoran AE, Okkenhaug K. The PI3K isoforms p110α and p110δ are essential for pre-B cell receptor signaling and B cell development. Sci Signal 2010; 3:ra60.
25. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, Vanhaesebroeck B. Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells. Blood 2006; 107:642-50. (Pubitemid 43076389)
26. Papakonstanti EA, Zwaenepoel O, Bilancio A, et al. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci 2008; 121:4124-33.
27. So L, Yea SS, Oak JS, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J Biol Chem 2013; 288:5718-31.
28. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase-Moving towards therapy. Biochim Biophys Acta 2008; 1784:159-85.
29. Taccioli GE, Amatucci AG, Beamish HJ, et al. Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers Severe Combined Immunodeficiency and radiosensitivity. Immunity 1998; 9:355-66. (Pubitemid 28462756)
30. Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008; 30:203-13. (Pubitemid 351626686)
31. Li Y, Wang X, Yue P, Tet al. Protein Phosphatase 2A and DNA-dependent protein kinase are involved in mediating Rapamycin-induced Akt phosphorylation. J Biol Chem 2013; 288:13215-24.
32. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 2013; 498:376-79.
33. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce Experimental Autoimmune Encephalomyelitis with different pathological phenotypes. J Immunol 2009; 183:7169-77.
34. Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, Rommel C, Firestein GS. PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid, arthritis. Amer J Pathol 2012; 180:1906-16.
35. Ali K, Camps M, Pearce WP, et al. Isoform-specific functions of phosphoinositide 3-kinases: p110δ but not p110γ promotes optimal allergic responses in vivo. J Immunol 2008; 180:2538-44.